Synergistic patterned neurodegeneration by APP and APOE4

APP 和 APOE4 的协同模式神经变性

基本信息

  • 批准号:
    9414391
  • 负责人:
  • 金额:
    $ 192.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-15 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Alzheimer disease (AD) is the most common cause of dementia and the 6th leading cause of death in the US, but the precise etiology of AD is unclear. Some cases of AD are clearly linked to the amyloid precursor protein (APP) gene which encodes a protein that is broken into toxic peptides and peptide aggregates that form plaques. Most cases of AD, however, are linked to a specific variant of the apolipid E (APOE) gene; over 40% of people with AD carry APOE4 and those who carry two APOE4 alleles have greater than 90% life-time risk of developing AD. Although APP has received intense study over several decades, it remains uncertain how APP leads to patterned neurodegeneration, and moreover how APOE4 synergizes with APP to contribute to AD. Important progress is being made with mouse models of AD; however, these approaches are often limited by the two years required for mice to display degeneration. To speed discovery, the Pierce-Shimomura lab recently developed a novel APP-related neurodegeneration model using the nematode C. elegans. The model expresses human APP pan- neuronally and intriguingly displays degeneration of specific subsets of neurons as the worm ages within only one week. This patterned neurodegeneration mimics an important hallmark of AD in humans in which neurodegeneration preferentially effects certain cholinergic neurons in brain regions associated with memory. The model also mimics an important aspect of human AD in that APP-induced neurodegeneration is accelerated by expressing APOE4, but not APOE3. Using cell-specific proteomics and the model of APP-related neurodegeneration in C. elegans, they aim to shed light on the molecular basis of patterned neurodegeneration in AD. Their approach addresses two critical questions in AD research: Why do specific neurons die? How does APOE4 increase risk of neurodegeneration? Finally, how does targeting a novel ligand, the sigma 2 receptor, conserved in worms and humans with small molecules relieve neurodegeneration? Knowledge gained from study in the C. elegans APP model can then be used to generate novel hypotheses to be tested in mammalian models of AD and may lead to novel therapeutics to treat AD.
项目摘要 阿尔茨海默病(AD)是痴呆症的最常见原因,也是老年人死亡的第六大原因。 US,但AD的确切病因尚不清楚。一些AD病例明显与淀粉样蛋白有关, 前体蛋白(APP)基因,其编码被分解成毒性肽和肽的蛋白质 形成斑块的聚集体。然而,大多数AD病例与特定的载脂蛋白变体有关。 E(APOE)基因;超过40%的AD患者携带APOE 4,携带两个APOE 4等位基因的人 超过90%的终生AD风险。虽然APP已经在几个方面得到了深入的研究, 几十年来,APP如何导致模式化的神经退行性变,以及APP如何导致模式化的神经退行性变, APOE 4与APP协同作用以促成AD。在小鼠模型方面取得了重要进展 然而,这些方法通常受到小鼠显示AD所需的两年时间的限制。 退化为了加速发现,皮尔斯-下村实验室最近开发了一种新的APP相关的 使用线虫C.优美的该模型表达了人类APP泛- 有趣的是,随着蠕虫体内神经元的老化, 只有一个星期。这种模式化的神经变性模拟了人类AD的一个重要标志, 这种神经变性优先影响脑区中的某些胆碱能神经元, 有记忆该模型还模拟了人AD的一个重要方面,即APP诱导的AD。 神经变性通过表达APOE 4而不是APOE 3加速。利用细胞特异性蛋白质组学 以及C.他们的目标是阐明 AD中的模式化神经变性的基础。他们的方法解决了AD中的两个关键问题 研究:为什么特定的神经元会死亡?APOE 4如何增加神经退行性变的风险?最后, 如何靶向一种新的配体,sigma 2受体,在蠕虫和人类中保守, 分子减轻神经退化通过对C. elegans APP模型可以 然后用于产生新的假设,以在AD的哺乳动物模型中进行测试,并可能导致 治疗AD的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JONATHAN THOMAS PIERCE其他文献

JONATHAN THOMAS PIERCE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JONATHAN THOMAS PIERCE', 18)}}的其他基金

High-throughput interrogation of autism risk genes: from molecules to behavior
自闭症风险基因的高通量询问:从分子到行为
  • 批准号:
    10639807
  • 财政年份:
    2023
  • 资助金额:
    $ 192.49万
  • 项目类别:
Systematic functional study of 21st chromosome ortholog overexpression in C. elegans
线虫第 21 号染色体直系同源物过表达的系统功能研究
  • 批准号:
    10651500
  • 财政年份:
    2022
  • 资助金额:
    $ 192.49万
  • 项目类别:
Systematic functional study of 21st chromosome ortholog overexpression in C. elegans
线虫第 21 号染色体直系同源物过表达的系统功能研究
  • 批准号:
    10841755
  • 财政年份:
    2022
  • 资助金额:
    $ 192.49万
  • 项目类别:
Systematic functional study of 21st chromosome ortholog overexpression in C. elegans
线虫第 21 号染色体直系同源物过表达的系统功能研究
  • 批准号:
    10432743
  • 财政年份:
    2022
  • 资助金额:
    $ 192.49万
  • 项目类别:
ANALYSIS OF MOTOR PATTERN SWITCHING BY DOPAMINE
多巴胺对运动模式切换的分析
  • 批准号:
    8291979
  • 财政年份:
    2011
  • 资助金额:
    $ 192.49万
  • 项目类别:
ANALYSIS OF MOTOR PATTERN SWITCHING BY DOPAMINE
多巴胺对运动模式切换的分析
  • 批准号:
    8478221
  • 财政年份:
    2011
  • 资助金额:
    $ 192.49万
  • 项目类别:
ANALYSIS OF MOTOR PATTERN SWITCHING BY DOPAMINE
多巴胺对运动模式切换的分析
  • 批准号:
    8846149
  • 财政年份:
    2011
  • 资助金额:
    $ 192.49万
  • 项目类别:
ANALYSIS OF MOTOR PATTERN SWITCHING BY DOPAMINE
多巴胺对运动模式切换的分析
  • 批准号:
    8162634
  • 财政年份:
    2011
  • 资助金额:
    $ 192.49万
  • 项目类别:
ANALYSIS OF MOTOR PATTERN SWITCHING BY DOPAMINE
多巴胺对运动模式切换的分析
  • 批准号:
    8664453
  • 财政年份:
    2011
  • 资助金额:
    $ 192.49万
  • 项目类别:
Adaptive tissue permeability to alcohol in C. elegans
线虫对酒精的适应性组织渗透性
  • 批准号:
    8064549
  • 财政年份:
    2010
  • 资助金额:
    $ 192.49万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 192.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了